Annual CFI
-$111.24 M
-$91.22 M-455.41%
31 December 2023
Summary:
BioMarin Pharmaceutical annual cash flow from investing activities is currently -$111.24 million, with the most recent change of -$91.22 million (-455.41%) on 31 December 2023. During the last 3 years, it has risen by +$255.07 million (+69.63%). BMRN annual CFI is now -142.08% below its all-time high of $264.35 million, reached on 31 December 2018.BMRN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$16.16 M
-$106.64 M-117.86%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly cash flow from investing activities is currently -$16.16 million, with the most recent change of -$106.64 million (-117.86%) on 30 September 2024. Over the past year, it has increased by +$48.81 million (+75.13%). BMRN quarterly CFI is now -103.49% below its all-time high of $462.68 million, reached on 31 December 2014.BMRN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$4.88 M
+$29.64 M+85.87%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM cash flow from investing activities is currently -$4.88 million, with the most recent change of +$29.64 million (+85.87%) on 30 September 2024. Over the past year, it has increased by +$106.37 million (+95.62%). BMRN TTM CFI is now -101.03% below its all-time high of $474.86 million, reached on 30 September 2018.BMRN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Cash From Investing Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | - | +75.1% | +95.6% |
3 y3 years | +69.6% | +70.8% | +98.7% |
5 y5 years | -258.6% | +67.0% | +84.3% |
BMRN Cash From Investing High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | -455.4% | +69.6% | -117.9% | +75.1% | at high | +98.7% |
5 y | 5 years | -455.4% | +69.6% | -115.1% | +93.5% | -105.0% | +98.7% |
alltime | all time | -142.1% | +90.6% | -103.5% | +97.8% | -101.0% | +99.6% |
BioMarin Pharmaceutical Cash From Investing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$16.16 M(-117.9%) | -$4.88 M(-85.9%) |
June 2024 | - | $90.48 M(-735.6%) | -$34.52 M(-63.8%) |
Mar 2024 | - | -$14.24 M(-78.1%) | -$95.47 M(-14.2%) |
Dec 2023 | -$111.24 M(+455.4%) | -$64.96 M(+41.8%) | -$111.24 M(+10.2%) |
Sept 2023 | - | -$45.80 M(-255.1%) | -$100.99 M(+28.5%) |
June 2023 | - | $29.53 M(-198.4%) | -$78.59 M(-43.0%) |
Mar 2023 | - | -$30.01 M(-45.1%) | -$137.82 M(+588.1%) |
Dec 2022 | -$20.03 M(-94.5%) | -$54.71 M(+133.8%) | -$20.03 M(-3.4%) |
Sept 2022 | - | -$23.40 M(-21.2%) | -$20.74 M(-82.3%) |
June 2022 | - | -$29.70 M(-133.8%) | -$117.19 M(-43.6%) |
Mar 2022 | - | $87.78 M(-258.4%) | -$207.74 M(-43.3%) |
Dec 2021 | -$366.31 M(+583.2%) | -$55.42 M(-53.8%) | -$366.31 M(+22.2%) |
Sept 2021 | - | -$119.85 M(-0.3%) | -$299.87 M(+309.0%) |
June 2021 | - | -$120.26 M(+69.9%) | -$73.32 M(-63.7%) |
Mar 2021 | - | -$70.79 M(-742.0%) | -$201.81 M(+276.4%) |
Dec 2020 | -$53.62 M(+72.8%) | $11.03 M(-89.7%) | -$53.62 M(-52.8%) |
Sept 2020 | - | $106.70 M(-142.9%) | -$113.54 M(-33.8%) |
June 2020 | - | -$248.75 M(-421.4%) | -$171.56 M(-277.1%) |
Mar 2020 | - | $77.40 M(-258.3%) | $96.86 M(-412.2%) |
Dec 2019 | -$31.03 M(-111.7%) | -$48.90 M(-200.4%) | -$31.03 M(-41.6%) |
Sept 2019 | - | $48.68 M(+147.5%) | -$53.09 M(-117.7%) |
June 2019 | - | $19.67 M(-139.0%) | $300.56 M(+5.2%) |
Mar 2019 | - | -$50.48 M(-28.9%) | $285.61 M(+8.0%) |
Dec 2018 | $264.35 M(-186.5%) | -$70.96 M(-117.6%) | $264.35 M(-44.3%) |
Sept 2018 | - | $402.33 M(+8420.2%) | $474.86 M(-232.8%) |
June 2018 | - | $4.72 M(-106.6%) | -$357.69 M(-11.1%) |
Mar 2018 | - | -$71.73 M(-151.4%) | -$402.24 M(+31.7%) |
Dec 2017 | -$305.46 M(-36.9%) | $139.55 M(-132.4%) | -$305.46 M(-59.5%) |
Sept 2017 | - | -$430.23 M(+980.4%) | -$754.65 M(+15.9%) |
June 2017 | - | -$39.82 M(-259.0%) | -$651.36 M(+21.5%) |
Mar 2017 | - | $25.05 M(-108.1%) | -$536.00 M(+10.7%) |
Dec 2016 | -$484.05 M(-59.0%) | -$309.65 M(-5.3%) | -$484.05 M(+410.3%) |
Sept 2016 | - | -$326.94 M(-532.8%) | -$94.85 M(-156.1%) |
June 2016 | - | $75.54 M(-1.9%) | $169.01 M(-148.1%) |
Mar 2016 | - | $77.00 M(-3.2%) | -$351.73 M(-70.2%) |
Dec 2015 | -$1.18 B(-700.8%) | $79.55 M(-226.1%) | -$1.18 B(+48.1%) |
Sept 2015 | - | -$63.08 M(-85.8%) | -$796.47 M(-13.5%) |
June 2015 | - | -$445.20 M(-40.7%) | -$920.86 M(+78.5%) |
Mar 2015 | - | -$750.87 M(-262.3%) | -$516.02 M(-362.8%) |
Dec 2014 | $196.33 M(-165.7%) | $462.68 M(-346.8%) | $196.33 M(-134.3%) |
Sept 2014 | - | -$187.48 M(+364.5%) | -$572.84 M(+49.9%) |
June 2014 | - | -$40.36 M(+4.8%) | -$382.05 M(+16.0%) |
Mar 2014 | - | -$38.52 M(-87.4%) | -$329.43 M(+10.2%) |
Dec 2013 | -$298.85 M(+52.8%) | -$306.49 M(-9351.0%) | -$298.85 M(+568.3%) |
Sept 2013 | - | $3.31 M(-73.0%) | -$44.72 M(-35.2%) |
June 2013 | - | $12.26 M(-254.4%) | -$68.98 M(-70.5%) |
Mar 2013 | - | -$7.94 M(-84.8%) | -$233.62 M(+19.4%) |
Dec 2012 | -$195.65 M(+118.5%) | -$52.35 M(+149.9%) | -$195.65 M(+9.8%) |
Sept 2012 | - | -$20.95 M(-86.3%) | -$178.21 M(-17.3%) |
June 2012 | - | -$152.38 M(-607.3%) | -$215.58 M(+245.0%) |
Mar 2012 | - | $30.04 M(-186.0%) | -$62.49 M(-30.2%) |
Dec 2011 | -$89.56 M | -$34.91 M(-40.1%) | -$89.56 M(+31.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2011 | - | -$58.32 M(-8360.8%) | -$68.26 M(+389.6%) |
June 2011 | - | $706.00 K(-76.2%) | -$13.94 M(-49.8%) |
Mar 2011 | - | $2.97 M(-121.8%) | -$27.77 M(-72.6%) |
Dec 2010 | -$101.34 M(+27.2%) | -$13.61 M(+239.8%) | -$101.34 M(-23.9%) |
Sept 2010 | - | -$4.00 M(-69.5%) | -$133.25 M(-22.3%) |
June 2010 | - | -$13.13 M(-81.4%) | -$171.47 M(+39.9%) |
Mar 2010 | - | -$70.60 M(+55.1%) | -$122.58 M(+53.9%) |
Dec 2009 | -$79.67 M(+317.6%) | -$45.52 M(+7.8%) | -$79.67 M(-9.5%) |
Sept 2009 | - | -$42.23 M(-218.1%) | -$88.03 M(+166.1%) |
June 2009 | - | $35.76 M(-229.2%) | -$33.09 M(-77.7%) |
Mar 2009 | - | -$27.69 M(-48.6%) | -$148.13 M(+676.5%) |
Dec 2008 | -$19.08 M(-87.4%) | -$53.88 M(-523.7%) | -$19.08 M(-44.1%) |
Sept 2008 | - | $12.72 M(-116.0%) | -$34.13 M(-176.2%) |
June 2008 | - | -$79.28 M(-178.2%) | $44.77 M(-156.5%) |
Mar 2008 | - | $101.36 M(-247.0%) | -$79.26 M(-47.5%) |
Dec 2007 | -$151.00 M(-21.6%) | -$68.94 M(-175.2%) | -$151.00 M(-12.7%) |
Sept 2007 | - | $91.63 M(-145.1%) | -$172.97 M(-50.5%) |
June 2007 | - | -$203.31 M(-786.3%) | -$349.24 M(+100.8%) |
Mar 2007 | - | $29.63 M(-132.6%) | -$173.90 M(-9.8%) |
Dec 2006 | -$192.69 M(-456.3%) | -$90.91 M(+7.4%) | -$192.69 M(+83.1%) |
Sept 2006 | - | -$84.65 M(+202.7%) | -$105.22 M(+498.5%) |
June 2006 | - | -$27.96 M(-358.2%) | -$17.58 M(-152.0%) |
Mar 2006 | - | $10.83 M(-414.9%) | $33.84 M(-37.4%) |
Dec 2005 | $54.07 M(-284.0%) | -$3.44 M(-215.1%) | $54.07 M(-15.2%) |
Sept 2005 | - | $2.99 M(-87.3%) | $63.76 M(-12.6%) |
June 2005 | - | $23.45 M(-24.5%) | $72.98 M(+389.7%) |
Mar 2005 | - | $31.07 M(+397.3%) | $14.90 M(-150.7%) |
Dec 2004 | -$29.38 M(-42.3%) | $6.25 M(-48.8%) | -$29.38 M(-58.0%) |
Sept 2004 | - | $12.21 M(-135.3%) | -$70.01 M(-25.3%) |
June 2004 | - | -$34.62 M(+161.9%) | -$93.66 M(+14.8%) |
Mar 2004 | - | -$13.22 M(-61.6%) | -$81.58 M(+60.1%) |
Dec 2003 | -$50.95 M(-171.9%) | -$34.38 M(+200.3%) | -$50.95 M(-399.2%) |
Sept 2003 | - | -$11.45 M(-49.2%) | $17.03 M(-63.2%) |
June 2003 | - | -$22.54 M(-229.4%) | $46.31 M(-37.5%) |
Mar 2003 | - | $17.42 M(-48.2%) | $74.13 M(+4.5%) |
Dec 2002 | $70.91 M(-161.1%) | $33.60 M(+88.5%) | $70.91 M(-274.0%) |
Sept 2002 | - | $17.83 M(+237.5%) | -$40.74 M(-38.4%) |
June 2002 | - | $5.28 M(-62.8%) | -$66.16 M(-41.5%) |
Mar 2002 | - | $14.20 M(-118.2%) | -$113.03 M(-2.7%) |
Dec 2001 | -$116.13 M(+6663.5%) | -$78.05 M(+928.6%) | -$116.13 M(+229.2%) |
Sept 2001 | - | -$7.59 M(-81.8%) | -$35.27 M(+42.3%) |
June 2001 | - | -$41.59 M(-474.8%) | -$24.78 M(+127.1%) |
Mar 2001 | - | $11.10 M(+295.3%) | -$10.91 M(+535.5%) |
Dec 2000 | -$1.72 M(-97.5%) | $2.81 M(-3.3%) | -$1.72 M(-83.8%) |
Sept 2000 | - | $2.90 M(-110.5%) | -$10.57 M(-83.0%) |
June 2000 | - | -$27.72 M(-236.6%) | -$62.28 M(+33.2%) |
Mar 2000 | - | $20.29 M(-435.4%) | -$46.76 M(-32.0%) |
Dec 1999 | -$68.75 M(+738.4%) | -$6.05 M(-87.6%) | -$68.75 M(+9.6%) |
Sept 1999 | - | -$48.80 M(+300.0%) | -$62.70 M(+351.1%) |
June 1999 | - | -$12.20 M(+617.2%) | -$13.90 M(+717.2%) |
Mar 1999 | - | -$1.70 M | -$1.70 M |
Dec 1998 | -$8.20 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual cash flow from investing activities?
- What is the all time high annual CFI for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly CFI year-on-year change?
- What is BioMarin Pharmaceutical TTM cash flow from investing activities?
- What is the all time high TTM CFI for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM CFI year-on-year change?
What is BioMarin Pharmaceutical annual cash flow from investing activities?
The current annual CFI of BMRN is -$111.24 M
What is the all time high annual CFI for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual cash flow from investing activities is $264.35 M
What is BioMarin Pharmaceutical quarterly cash flow from investing activities?
The current quarterly CFI of BMRN is -$16.16 M
What is the all time high quarterly CFI for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly cash flow from investing activities is $462.68 M
What is BioMarin Pharmaceutical quarterly CFI year-on-year change?
Over the past year, BMRN quarterly cash flow from investing activities has changed by +$48.81 M (+75.13%)
What is BioMarin Pharmaceutical TTM cash flow from investing activities?
The current TTM CFI of BMRN is -$4.88 M
What is the all time high TTM CFI for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM cash flow from investing activities is $474.86 M
What is BioMarin Pharmaceutical TTM CFI year-on-year change?
Over the past year, BMRN TTM cash flow from investing activities has changed by +$106.37 M (+95.62%)